Search
  1. Home
  2. Southern Africa
  3. South Africa

Anti-AIDS drug faces rejection

    JOHANNESBURG

    An antiretroviral drug used to block the transmission of HIV from mother to child could soon be banned by South Africa's Medicines Control Council (MCC) on grounds of safety.

    The HIV/AIDS drug nevirapine received approval for local use when activists won a court order forcing the government to provide it to HIV-positive mothers last year.

    However, despite a recent thumbs-up by the World Health Organisation (WHO), the MCC could deregister the drug after rejecting results of a key Ugandan study on nevirapine's efficacy.

    MCC director, Precious Matsoso, said the 1999 study had numerous flaws and registration would be revoked unless the German manufacturer, Boehringer-Ingelheim, provided additional safety and effectiveness data within 90 days.

    "We have to be cautious," Matsoso told Reuters. "If information is available that meets rigorous scientific standards, we will look at it."

    This article was produced by IRIN News while it was part of the United Nations Office for the Coordination of Humanitarian Affairs. Please send queries on copyright or liability to the UN. For more information: https://shop.un.org/rights-permissions

    Share this article

    Our ability to deliver compelling, field-based reporting on humanitarian crises rests on a few key principles: deep expertise, an unwavering commitment to amplifying affected voices, and a belief in the power of independent journalism to drive real change.

    We need your help to sustain and expand our work. Your donation will support our unique approach to journalism, helping fund everything from field-based investigations to the innovative storytelling that ensures marginalised voices are heard.

    Please consider joining our membership programme. Together, we can continue to make a meaningful impact on how the world responds to crises.

    Become a member of The New Humanitarian

    Support our journalism and become more involved in our community. Help us deliver informative, accessible, independent journalism that you can trust and provides accountability to the millions of people affected by crises worldwide.

    Join